OmniComm Systems, Inc. (OTC: OMCM.OB), a global provider of eClinical solutions announced that it released TrialOne, a fully integrated, MS .NET, web‐based solution designed to automate the Phase I Clinical Trial Process. TrialOne provides web‐based tools used to recruit study volunteers, schedule screening appointments, collect screening data, directly capture real‐time data, track sample transfers and address the unique requirements of early phase studies. Within each study, real‐time electronic data is captured and validated at the subject’s bedside or at a subject queuing station. Enhanced workflow technology automates sample processing throughout the lab. TrialOne supports a myriad of directly attached biomedical monitoring devices such as the GE Healthcare DINAMAP® family of vital signs monitors and various ECG devices.
TrialOne enables Phase I Clinics to share data with other stakeholders via the internet and provides a flexible ad‐hoc reporting tool to help export and report data in various formats including Adobe® PDF, Microsoft® Excel and Word. Further extensibility of the TrialOne suite via integration to our flagship EDC product, TrialMaster®, using OmniConnect™, our enhanced web services API, and an integrated pharmacy module is planned for release later this year.
“TrialOne is the only available product that handles all aspects of the Phase I process from subject recruitment and clinical wokflow management to laboratory sample management,” said OmniComm’s CTO, Randy Smith.
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.